enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 1,263 shares, a decline of 38.5% from the December 15th total of 2,052 shares. Based on an average daily volume of 4,073 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 4,073 shares, the short-interest ratio is presently 0.3 days.

enGene Stock Performance

NASDAQ ENGNW traded down $0.10 on Friday, reaching $2.99. The company had a trading volume of 512 shares, compared to its average volume of 33,402. enGene has a fifty-two week low of $0.51 and a fifty-two week high of $3.80. The business has a 50 day moving average of $2.67 and a two-hundred day moving average of $1.62.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.